Synopsis
Blade Therapeutics is a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that impact millions of people worldwide.
The company specialises in novel biological pathways, such as autotaxin/LPA and calpain biology, which are foundational to cell- and tissue-damage responses associated with fibrotic and neurodegenerative diseases. This focused approach offers the potential to produce disease-modifying, life-saving therapies.
Since its founding in 2015, the company has assembled critical leadership expertise and a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development. Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies, including a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains, which are designed for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases.
testimonials
Wendye Robbins
CEO, Blade Therapeutics
